The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease

التفاصيل البيبلوغرافية
العنوان: The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease
المؤلفون: Mohsen Taghizadeh, Zahra Hamedifard, Zatollah Asemi, Maryam Ghotbi, Alireza Farrokhian, Željko Reiner, Fereshteh Bahmani
المصدر: Lipids in Health and Disease, Vol 19, Iss 1, Pp 1-9 (2020)
Lipids in Health and Disease
سنة النشر: 2020
مصطلحات موضوعية: Blood Glucose, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Zinc / therapeutic use, Clinical Biochemistry, Blood lipids, Coronary Disease, Antioxidants / analysis, Gastroenterology, Antioxidants, Endocrinology, C-Reactive Protein / analysis, Magnesium / pharmacology, Nitrites / blood, Insulin, Medicine, Magnesium, lcsh:RC620-627, Cholesterol, HDL / blood, Coronary Disease / drug therapy, Coronary Disease / blood, Coronary heart disease, Insulin / blood, Zinc, lcsh:Nutritional diseases. Deficiency diseases, Diabetes Mellitus, Type 2 / blood, C-Reactive Protein, Lipidology, medicine.medical_specialty, chemistry.chemical_element, Clinical nutrition, Metabolic status, Placebo, Double-Blind Method, Internal medicine, Type 2 diabetes mellitus, Humans, Magnesium / therapeutic use, Nitrites, Glycemic, business.industry, Research, Cholesterol, HDL, Biochemistry (medical), Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, chemistry, Zinc / pharmacology, Dietary Supplements, business, Diabetes Mellitus, Type 2 / drug therapy
الوصف: Background The present research aimed to analyze the impacts of magnesium and zinc supplements on glycemic control, serum lipids, and biomarkers of oxidative stress and inflammation in patients suffering from coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM). Methods According to the research design, a randomized, double-blind, placebo-controlled trial has been implemented on 60 subjects suffering from CHD and T2DM. Therefore, participants have been randomly divided into 2 groups for taking placebo (n = 30) or 250 mg magnesium oxide plus 150 mg zinc sulfate (n = 30) for 12 weeks. Results Magnesium and zinc significantly decreased fasting plasma glucose (FPG) (β − 9.44 mg/dL, 95% CI, − 18.30, − 0.57; P = 0.03) and insulin levels (β − 1.37 μIU/mL, 95% CI, − 2.57, − 0.18; P = 0.02). Moreover, HDL-cholesterol levels significantly enhanced (β 2.09 mg/dL, 95% CI, 0.05, 4.13; P = 0.04) in comparison to the placebo. There was an association between magnesium and zinc intake, and a significant decrease of C-reactive protein (CRP) (β − 0.85 mg/L, 95% CI, − 1.26, − 0.45; P P = 0.003) and total antioxidant capacity (TAC) (β 43.44 mmol/L, 95% CI, 3.39, 83.50; P = 0.03) when compared with placebo. Furthermore, magnesium and zinc significantly reduced the Beck Depression Inventory index (BDI) (β − 1.66; 95% CI, − 3.32, − 0.009; P = 0.04) and Beck Anxiety Inventory (BAI) (β − 1.30; 95% CI, − 2.43, − 0.16; P = 0.02) when compared with the placebo. Conclusions In patients with T2DM and CHD, the 12-week intake of magnesium plus zinc had beneficial effects on FPG, HDL-cholesterol, CRP, insulin, total nitrite, TAC levels, and BDI and BAI score. This suggests that magnesium and zinc co-supplementation may be beneficial for patients with T2DM and CHD. Further studies on more patients and lasting longer are needed to determine the safety of magnesium and zinc co-supplementation. Trial registration Current Controlled Trials http://www.irct.irTest: IRCT20130211012438N31 at 11 May 2019 of registration. This study retrospectively registered.
وصف الملف: application/pdf
اللغة: English
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::353c1f023bdb3580e9810031c7926f18Test
https://doi.org/10.1186/s12944-020-01298-4Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....353c1f023bdb3580e9810031c7926f18
قاعدة البيانات: OpenAIRE